Agios Makes Case For Pyrukynd Approval In SCD Despite Mixed Phase III Results
Hemoglobin Responders Had Meaningful Pain, Fatigue Improvements
Pyrukynd significantly improved hemolysis in sickle cell disease, but did not significantly reduce pain events (Shutterstock) 
